FDA Brief

Warning letters Drugs

FDA warning letter to

Eco Lips, Inc.

High riskIssued Sep 20, 2022Posted Apr 18, 2023Division of Pharmaceutical Quality Operations III

FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.

What happened

FDA inspected Eco Lips, Inc.'s drug manufacturing facility in Cedar Rapids, Iowa, from March 22 to March 24, 2022. The inspection found inadequate stability testing and expiration dates, failed test results that were not investigated before batches were released, missing process validation for most sunscreen groups, inadequate cleaning validation, and incomplete annual product reviews. FDA said these were repeat violations from 2019 and 2021 inspections and that manufacturing did not meet Current Good Manufacturing Practice (CGMP), the FDA's drug manufacturing rules.

What FDA found

  1. Eco Lips did not have an adequate stability program or data to support expiration dates for its over-the-counter drug products.

    21 CFR 211.166(a)
  2. Eco Lips did not thoroughly investigate batches that failed tests and released some batches even after test results failed.

    21 CFR 211.192
  3. Eco Lips had not validated the manufacturing processes for seven of nine over-the-counter sunscreen product groups.

    21 CFR 211.100(a)
  4. Eco Lips did not validate cleaning of shared equipment, did not test for cleaning-agent residue removal, and lacked data on how long cleaning samples could be held.

    21 CFR 211.67(b)
  5. Eco Lips did not complete annual product reviews for all its drug products.

    21 CFR 211.180(e)

What FDA wants

FDA tells Eco Lips to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence, including the requested assessments and plans. If it cannot complete corrective actions in that time, it must explain the delay and give a completion schedule.

Who should pay attention

  • brands that buy over-the-counter drug products from Eco Lips as a contract manufacturer
  • retailers and distributors selling Eco Lips sunscreen drug products
  • quality teams overseeing contract manufacturers of over-the-counter drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk